Home / Healthcare / Mitsubishi Tanabe Pharma Corporation - Product Pipeline Review - 2015

Mitsubishi Tanabe Pharma Corporation - Product Pipeline Review - 2015

Published: Aug 2015 | No Of Pages: 119 | Published By: Global Markets Direct

Mitsubishi Tanabe Pharma Corporation - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'Mitsubishi Tanabe Pharma Corporation - Product Pipeline Review - 2015', provides an overview of the Mitsubishi Tanabe Pharma Corporation's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Mitsubishi Tanabe Pharma Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Mitsubishi Tanabe Pharma Corporation including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Mitsubishi Tanabe Pharma Corporation's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Mitsubishi Tanabe Pharma Corporation's pipeline products

Reasons to buy

- Evaluate Mitsubishi Tanabe Pharma Corporation's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Mitsubishi Tanabe Pharma Corporation in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Mitsubishi Tanabe Pharma Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Mitsubishi Tanabe Pharma Corporation and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Mitsubishi Tanabe Pharma Corporation
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Mitsubishi Tanabe Pharma Corporation and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Mitsubishi Tanabe Pharma Corporation Snapshot 5
Mitsubishi Tanabe Pharma Corporation Overview 5
Key Information 5
Key Facts 5
Mitsubishi Tanabe Pharma Corporation - Research and Development Overview 6
Key Therapeutic Areas 6
Mitsubishi Tanabe Pharma Corporation - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Combination Treatment Modalities 12
Pipeline Products - Partnered Products 13
Pipeline Products - Out-Licensed Products 15
Mitsubishi Tanabe Pharma Corporation - Pipeline Products Glance 17
Mitsubishi Tanabe Pharma Corporation - Late Stage Pipeline Products 17
Mitsubishi Tanabe Pharma Corporation - Clinical Stage Pipeline Products 19
Mitsubishi Tanabe Pharma Corporation - Early Stage Pipeline Products 21
Mitsubishi Tanabe Pharma Corporation - Drug Profiles 23
canagliflozin 23
edaravone 25
infliximab 27
teneligliptin 30
(canagliflozin + metformin hydrochloride XR) 32
(canagliflozin + teneligliptin) 33
avanafil 34
cariprazine 35
encenicline hydrochloride 37
fingolimod hydrochloride 40
telaprevir 43
bepotastine besylate 47
masilukast 49
MIN-117 50
MT-1303 51
MT-210 52
MT-3995 54
MT-4580 55
NU-300 56
TA-7906 57
GB-1057 58
MP-124 59
MP-157 60
MT-0814 61
MT-8554 62
Antibody to Inhibit RGM for Spinal Cord Injury 63
Monoclonal Antibody for Inflammatory Disorders 64
Small Molecule to Block Sodium Channels for Ischemic Stroke 65
Small Molecules to Block Sodium and hERG Channel for Ischemic Stroke 66
Small Molecules to Inhibit DPP-IV for Hyperglycemia 67
Small Molecules to Inhibit GSK-3 Beta for Neurodegenerative Diseases 68
TA-3404 69
Y-320 70
Monoclonal Antibodies for Undisclosed Indication 72
Monoclonal Antibody for Cancer 73
Small Molecule to Inhibit PDE5 for Undisclosed Indication 74
Small Molecule to Inhibit S-Adenosyl-L-Homocysteine Hydrolase for Undisclosed Indication 75
T-6932 76
Mitsubishi Tanabe Pharma Corporation - Pipeline Analysis 77
Mitsubishi Tanabe Pharma Corporation - Pipeline Products by Target 77
Mitsubishi Tanabe Pharma Corporation - Pipeline Products by Route of Administration 79
Mitsubishi Tanabe Pharma Corporation - Pipeline Products by Molecule Type 80
Mitsubishi Tanabe Pharma Corporation - Pipeline Products by Mechanism of Action 81
Mitsubishi Tanabe Pharma Corporation - Recent Pipeline Updates 83
Mitsubishi Tanabe Pharma Corporation - Dormant Projects 104
Mitsubishi Tanabe Pharma Corporation - Discontinued Pipeline Products 105
Discontinued Pipeline Product Profiles 105
Mitsubishi Tanabe Pharma Corporation - Company Statement 109
Mitsubishi Tanabe Pharma Corporation - Locations And Subsidiaries 110
Head Office 110
Other Locations & Subsidiaries 110
Appendix 114
Methodology 114
Coverage 114
Secondary Research 114
Primary Research 114
Expert Panel Validation 114
Contact Us 114
Disclaimer 115

Mitsubishi Tanabe Pharma Corporation, Key Information 9
Mitsubishi Tanabe Pharma Corporation, Key Facts 9
Mitsubishi Tanabe Pharma Corporation - Pipeline by Indication, 2015 11
Mitsubishi Tanabe Pharma Corporation - Pipeline by Stage of Development, 2015 14
Mitsubishi Tanabe Pharma Corporation - Monotherapy Products in Pipeline, 2015 15
Mitsubishi Tanabe Pharma Corporation - Combination Treatment Modalities in Pipeline, 2015 16
Mitsubishi Tanabe Pharma Corporation - Partnered Products in Pipeline, 2015 17
Mitsubishi Tanabe Pharma Corporation - Partnered Products/ Combination Treatment Modalities, 2015 18
Mitsubishi Tanabe Pharma Corporation - Out-Licensed Products in Pipeline, 2015 19
Mitsubishi Tanabe Pharma Corporation - Out-Licensed Products/ Combination Treatment Modalities, 2015 20
Mitsubishi Tanabe Pharma Corporation - Pre-Registration, 2015 21
Mitsubishi Tanabe Pharma Corporation - Phase III, 2015 22
Mitsubishi Tanabe Pharma Corporation - Phase II, 2015 23
Mitsubishi Tanabe Pharma Corporation - Phase I, 2015 24
Mitsubishi Tanabe Pharma Corporation - Preclinical, 2015 25
Mitsubishi Tanabe Pharma Corporation - Discovery, 2015 26
Mitsubishi Tanabe Pharma Corporation - Pipeline by Target, 2015 81
Mitsubishi Tanabe Pharma Corporation - Pipeline by Route of Administration, 2015 83
Mitsubishi Tanabe Pharma Corporation - Pipeline by Molecule Type, 2015 84
Mitsubishi Tanabe Pharma Corporation - Pipeline Products by Mechanism of Action, 2015 85
Mitsubishi Tanabe Pharma Corporation - Recent Pipeline Updates, 2015 87
Mitsubishi Tanabe Pharma Corporation - Dormant Developmental Projects,2015 108
Mitsubishi Tanabe Pharma Corporation - Discontinued Pipeline Products, 2015 109
Mitsubishi Tanabe Pharma Corporation, Other Locations 114
Mitsubishi Tanabe Pharma Corporation, Subsidiaries 115

Mitsubishi Tanabe Pharma Corporation - Pipeline by Top 10 Indication, 2015 11
Mitsubishi Tanabe Pharma Corporation - Pipeline by Stage of Development, 2015 14
Mitsubishi Tanabe Pharma Corporation - Monotherapy Products in Pipeline, 2015 15
Mitsubishi Tanabe Pharma Corporation - Partnered Products in Pipeline, 2015 17
Mitsubishi Tanabe Pharma Corporation - Out-Licensed Products in Pipeline, 2015 19
Mitsubishi Tanabe Pharma Corporation - Pipeline by Top 10 Target, 2015 81
Mitsubishi Tanabe Pharma Corporation - Pipeline by Top 10 Route of Administration, 2015 83
Mitsubishi Tanabe Pharma Corporation - Pipeline by Top 10 Molecule Type, 2015 84
Mitsubishi Tanabe Pharma Corporation - Pipeline Products by Top 10 Mechanism of Action, 2015 85

Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +